… Heterogeneity has been documented in trajectories of symptom change during antidepressant
treatment for major depressive disorder (MDD). It is unclear whether distinct trajectories of …

… to the anti-depressive nature of desvenlafaxine and the subsequent … desvenlafaxine 50 mg
and 100 mg are effective in treating … inflammatory process, desvenlafaxine 50 mg may be an …

… be different for several reasons such as tolerability problems, access barriers, poor adherence
to … that only 50% of the patients with a major depressive episode treated with citalopram …

… depressive patients: one group was desvenlafaxine-naïve; the other was made up of patients
switched to desvenlafaxine … , which indicated a better profile of sexual tolerability compared …

… Desvenlafaxine (PRISTIQ), a selective serotonin and norepinephrine reuptake inhibitor (SNRI),
was licensed by the FDA in 2008 to treat major depressive … efficacy and tolerability. Both …

… efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major
depressive … Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebocontrolled …

… tolerability, the dose could be titrated upward to 150 mg/d at … efficacy of SNRIs and SSRIs in
their study on the treatment of … the high doses of desvenlafaxine (100–200 mg/d) that did not …

… for the treatment of major depressive episodes in … tolerability compared to other
antidepressants. It thus did not recommend duloxetine as a firstline treatment for major depressive …

… of dizziness, while desvenlafaxine, sertraline, and … desvenlafaxine, paroxetine, venlafaxine,
and vortioxetine had reasonable efficacy, acceptability, and tolerability in the treatment …

… of major depressive disorder: A pooled analysis of 4 Chinese clinical … Efficacy, safety,
and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a …